simvastatin has been researched along with Adrenoleukodystrophy in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| De Jong, J; Rubio-Gozalbo, E; Smeitink, JA; Verrips, A; Willemsen, MA | 1 |
| Aubourg, P; Cartier, N; Guidoux, S; Rocchiccioli, F | 1 |
| Avellino, C; Cappa, M; Di Biase, A; Masella, R; Salvati, S; Sforza, F; Varí, R | 1 |
| Forget, PP; Rubio-Gozalbo, ME; Spaapen, LJ; van Waardenburg, DA; Verrips, A; Vroomen, PC | 1 |
2 trial(s) available for simvastatin and Adrenoleukodystrophy
| Article | Year |
|---|---|
Simvastatin and plasma very-long-chain fatty acids in X-linked adrenoleukodystrophy.
Topics: Adrenoleukodystrophy; Child; Fatty Acids; Humans; Hypolipidemic Agents; Simvastatin | 2000 |
Susceptibility to oxidation of plasma low-density lipoprotein in X-linked adrenoleukodystrophy: effects of simvastatin treatment.
Topics: Adrenoleukodystrophy; Humans; Hydrogen Peroxide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kinetics; Lipid Peroxidation; Lipid Peroxides; Lipoproteins, LDL; Male; Oxidation-Reduction; Oxidative Stress; Phenotype; Simvastatin | 2000 |
2 other study(ies) available for simvastatin and Adrenoleukodystrophy
| Article | Year |
|---|---|
Simvastatin does not normalize very long chain fatty acids in adrenoleukodystrophy mice.
Topics: Adrenal Glands; Adrenoleukodystrophy; Animals; Body Weight; Brain; Cholesterol; Fatty Acids; Liver; Male; Mice; Mice, Inbred C57BL; Myocardium; Simvastatin; Time Factors | 2000 |
Neuroleptic malignant syndrome during zuclopenthixol therapy in X-linked cerebral adrenoleukodystrophy.
Topics: Adrenoleukodystrophy; Antipsychotic Agents; Child; Child Behavior Disorders; Clopenthixol; Humans; Male; Neuroleptic Malignant Syndrome; Simvastatin | 2001 |